Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

TitleGenetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Publication TypeJournal Article
Year of Publication2017
AuthorsReddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg M-L, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SYoung, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong Y-L, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS
JournalCell
Volume171
Issue2
Pagination481-494.e15
Date Published2017 Oct 05
ISSN1097-4172
KeywordsAntineoplastic Agents, Cell Line, Tumor, Cells, Cultured, CRISPR-Cas Systems, Exome, Female, Gene Expression Profiling, Humans, Lymphoma, Large B-Cell, Diffuse, Male, Rituximab
Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity poses a major barrier to understanding the genetic basis of the disease and its response to therapy. Here, we performed an integrative analysis of whole-exome sequencing and transcriptome sequencing in a cohort of 1,001 DLBCL patients to comprehensively define the landscape of 150 genetic drivers of the disease. We characterized the functional impact of these genes using an unbiased CRISPR screen of DLBCL cell lines to define oncogenes that promote cell growth. A prognostic model comprising these genetic alterations outperformed current established methods: cell of origin, the International Prognostic Index comprising clinical variables, and dual MYC and BCL2 expression. These results comprehensively define the genetic drivers and their functional roles in DLBCL to identify new therapeutic opportunities in the disease.

DOI10.1016/j.cell.2017.09.027
Alternate JournalCell
PubMed ID28985567
PubMed Central IDPMC5659841
Grant ListR01 CA193655 / CA / NCI NIH HHS / United States
T32 GM071340 / GM / NIGMS NIH HHS / United States
Related Faculty: 
Amy Chadburn, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700